
Abstract Small molecule inhibitors of glutaminase (GSL1) are described as potential treatment of metabolic diseases including obesity, diabetes, liver diseases, muscular atrophy and atherosclerosis. Glutaminolysis is an alternative to glycosis as a source of carbon for energy homeostasis and is a major source of energy in the brain and other organs. Glutaminase (GSL1) is a mitochondrial enzyme converting glutamine into glutamate through glutaminolysis. Excessive glutaminolysis is associated with accelerated aging.
Abstract p53 is frequently inactivated through overexpression of MDM2 and MDM4, highlighting the need for effective MDM2/MDM4 dual inhibitors. In this work, an MDM2/MDM4-based virtual screening led to the identification of etrasimod as dual MDM2/MDM4 inhibitor. Guided by structural insights, rational modification of the cyclopentyl substituent afforded a series of six cyclopenta[b]indole derivatives designed to improve interactions in the hydrophobic Leu-26 pocket in both proteins. This optimization resulted in enhanced dual inhibitory activity, with the most potent analogue bearing a 3,4-dichlorophenyl substituent exhibiting IC50 values of 1.6 μM (MDM2) and 2.6 μM (MDM4) in binding assays. Moreover, mechanistic studies in SJSA-1 cells demonstrated a significant increase in p53 steady-state protein levels, as well as cleaved caspase-3 and cleaved PARP, consistent with p53 pathway engagement and activation of apoptosis. Overall, this study identifies cyclopenta[b]indoles as a new chemical scaffold for dual MDM2/MDM4 inhibition providing a basis for further biochemical and cellular optimization.
KRAS mutations are key drivers of oncogenesis in numerous cancer types, with KRAS(G12V), KRAS(G12D), and KRAS(G12C) alterations being the most prevalent. While inhibitors targeting KRAS(G12C) have shown clinical success, challenges remain in addressing the broader spectrum of KRAS mutations. Our initial effort to discover a broad-based KRAS therapeutic was guided by a scaffold-hopping campaign inspired by compounds with demonstrated switch-II pocket engagement. While macrocyclization of a 2-(1-pyrazolyl)pyrimidine core prototype did not yield suitable in vitro activity at the outset, it provided valuable insights into subsequent efforts. Refinement of our approach led to compound 1, which demonstrated high KRAS(G12V) binding affinity and concomitant biochemical potency in KRAS(G12V/G12D) mutants. Further physicochemical improvements led to the design of 2-(3-isoxazolyl)pyrimidine macrocycles with improved permeability and in vitro mutant KRAS cellular activity.
Patients with metastatic breast cancer have a dismal five-year survival rate of 28% because these cancers develop resistance to multiple treatment modalities; thus, novel therapies are desperately needed. Interferon signaling gene signatures and the expression of interferon stimulated gene 15 (ISG15) have been linked to resistance to chemotherapy, radiotherapy, immunotherapy, and targeted therapy in patients, but there are no therapies that target ISG15 or the enzymatic machinery that enables its covalent conjugation to substrate proteins, such as its activating E1 enzyme UBA7. In this pilot study, we established an AlphaLISA-based high-throughput assay to identify inhibitors of the ISG15-UBA7 interaction. The assay demonstrated strong performance characteristics for high-throughput screening with a Z ' factor of 0.69, indicating excellent robustness and sensitivity. Screening a library of 880 compounds yielded three hits that inhibited the ISG15-UBA7 interaction. Two of these compounds were also found to reduce ISGylation in cell-based assays. Overall, these findings highlight the utility of AlphaLISA as a scalable platform for high-throughput screening of drug-like inhibitors targeting the ISGylation pathway.